UK Markets closed

Jazz Pharmaceuticals plc (JAZZ)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
148.53-1.00 (-0.67%)
At close: 04:00PM EDT
148.53 0.00 (0.00%)
After hours: 04:33PM EDT
Sign in to post a message.
  • k
    kC
    $SLS conversation
    $XBI closed RED - $SLS Up Big and Green
    Divergency = a short emergency, 2 Massive Trial Results in 4 or 5 weeks and a Billion Dollar FDA Approval next year. SLS shares are Cheap As F - $50M Market cap when $jazz paid $1.5B for a direct comp, only a matter of time.
  • J
    Joe
    $SLS conversation
    Massively undervalued Equity $Jazz paid $1.5B for Cpxx when it released its p3 data. SLS now trades for .0375 or 3.75% of what it will be worth when the AML Approval happens in 12 months no or sooner when the idmc halts the trial for efficacy.
  • J
    Joe
    $SLS conversation
    $Jazz paid $1.5B for Cpxx AML agent, similar to Gps P3 market. Equal to $75/sls share +2,770% ROI FDA approval 12 months If Idmc doesn’t halt this sooner.
  • C
    CMOREGAINS
    Looking forward to tomorrows earnings report! This is currently one of my few stocks in the green (for now).
  • T
    Tim
    Interesting Jazz is down $7 pre market. Very bizarre trading all ways around. Maybe a decision is imminent?
  • R
    Real Immuno Investor 10
    $SLS conversation
    Can any of the Short Lowlife Refute this Direct Market Comp? for AML only ?
    SLS has a MKT Cap of $113M vs $1.5B $JAZZ paid for $CPXX when it released its p3 data - GPS p3 data in months - equates to $95 Per SLS share. https://www.wsj.com/articles/jazz-pharmaceuticals-agrees-to-buy-celator-for-about-1-5-billion-1464686352

    Cantor Fitz Analysts proj revenue of $200M in initial Niche cr2 setting.
    SELLAS is a late-stage immune-oncology company that is focused on novel cancer vaccines. The lead drug candidate, galinpepimut-S (GPS), is a peptide vaccine that target Wilms tumor 1 and is in a Phase 3 trial for acute myeloid leukemia (AML).

    Even in the initial niche target population of AML patients after second complete remission, “we project the peak sales to be about $200-million” Li Watsek

    “Overtime, we think GPS has the potential to broaden into AML patients after first complete remission, as well as in other indications with combinations”

    Gps is Priceless for AML patients. What will big pharma pay for $800M in Potential AML Revenue?

    Buy and Hold
    Jazz Pharmaceuticals agreed to buy Celator Pharmaceuticals in a roughly $1.5 billion deal that represents a huge premium for a company with a promising leukemia drug but no revenue.
    Jazz Pharmaceuticals agreed to buy Celator Pharmaceuticals in a roughly $1.5 billion deal that represents a huge premium for a company with a promising leukemia drug but no revenue.
    www.wsj.com
  • C
    CMOREGAINS
    So much for this being my only stock that "was" in the green.
  • A
    Adrien
    been holding for months and sold at 156. I feel I have missed something in my understanding on when to sell
  • Y
    You Should Know
    Is this the US govt owned stock where they use their patent on pot while making it still illegal for the competition? Yes, YES IT IS!
  • B
    Berlin 68
    $SLS conversation
    4 News hits before the FDA later this year. 1. Nps Twin Glsi trial, 2 NPs license, 3 Gps+Opdivo Meso trial data, 4 Gps + Keytruda ovarian data unlocked.
    $17, then $70 and $170 in 2022 $MRK Gps Keytruda Phase 2 data is now locked, and will be definitively Binary. There are no effective treatments for platinum Resistant OC patients. Should these results -Mid Year confirm earlier data (100% Survival Rates), Gps is immediately worth $1B just for OC. Also, AML Phase 3 Approval zone 4 months away. $Jazz Paid 1.5B for $cpxx when it reported its P3 data .. Tuck a Few away while they’re on sale and ‘stay tuned.’
    https://www.globenewswire.com/news-release/2021/06/30/2255695/0/en/SELLAS-Reports-Promising-Updated-Clinical-Data-and-Initial-Immune-Response-Profiles-from-Ongoing-Phase-1-2-Study-of-Galinpepimut-S-GPS-Combined-with-Keytruda-for-Treating-WT1-Advan.html
    Updated Data Shows 100 Percent of Patients Alive and 45.5 Percent Continuing Investigational Therapy as of the Latest Follow-Up Immune Data Shows GPS...
    Updated Data Shows 100 Percent of Patients Alive and 45.5 Percent Continuing Investigational Therapy as of the Latest Follow-Up Immune Data Shows GPS...
    www.globenewswire.com
  • A
    Adrien
    Do you see a bearish divergence or are we building support ?
  • t
    thomas
    I have many quality stocks this is the only one that was up today every other one was down I’m about ready to cash out and watch
  • B
    BORED#V+MUSK
    Time to buy the puts folks 155 looking tasty. the lawsuit is just the start see you guys sub 100's want to long buy BDX or ABT this thing toast.
  • C
    CMOREGAINS
    This is one of the only stocks I own that I like right now and I'm only up 1%. The Cannabis sector has been terrible but this is holding up nice. I plan on holding this for a long time and feel confident unlike most all my holdings.
  • R
    Real Immuno Investor 10
    $SLS conversation
    After CPXX reported its p3 data, Jazz bought Cpxx for $1.5B their AML drug isn't half the drug GPS is - SLS trades for .08B $Jazz Pharmaceuticals said it will acquire Celator in a deal worth a total of $1.5 billion. The Irish company will gain access to the Ewing, NJ-based company's lead experimental blood cancer drug Vyxeos (CPX-351), which just last week gained an FDA “breakthrough therapy” designation.

    The FDA’s designation--which speeds up its review of a new medicine--is for patients with therapy-related AML (t-AML) or AML with myelodysplasia-related changes (AML-MRC).

    A recent Phase III trial met its primary endpoint by showing statistically significant improvement in overall survival; detailed data will be presented at ASCO next week.

    Its current data for the drug showed median overall survival for patients treated with Vyxeos was 9.56 months compared with 5.95 months--a 3.61-month improvement in favor of Celator’s treatment against a chemotherapy agent known as 7+3.
  • B
    Berlin 68
    $SLS conversation
    4 Due News hits before the FDA Approval later this year.
    Nps Twin Glsi trial, NPs license, Gps+Opdivo Meso trial data, and Gps + Keytruda ovarian cancer data unlocked.
    $16, then $60 and $160 in 2022 $MRK Gps Keytruda Phase 2 data is now locked, and will be definitively Binary. There are no effective treatments for platinum Resistant OC patients. Should these results -Mid Year confirm earlier data (100% Survival Rates), Gps is immediately worth $1B just for OC. Also, AML Phase 3 Approval zone 4 months away. $Jazz Paid 1.5B for $cpxx when it reported its P3 data .. Tuck a Few away while they’re on sale and ‘stay tuned.’
    https://www.globenewswire.com/news-release/2021/06/30/2255695/0/en/SELLAS-Reports-Promising-Updated-Clinical-Data-and-Initial-Immune-Response-Profiles-from-Ongoing-Phase-1-2-Study-of-Galinpepimut-S-GPS-Combined-with-Keytruda-for-Treating-WT1-Advan.html
  • N
    Noah
    LOVE IT BABY!
  • B
    Berlin 68
    $SLS conversation
    4 News hits before the FDA AML Approval later this year. 1. Nps Twin Glsi trial, 2 NPs license, 3 Gps+Opdivo Meso trial data, and 4 Gps + Keytruda ovarian cancer data unlocked.
    $16, then $60 and $160 in 2022 $MRK Gps Keytruda Phase 2 data is now locked, and will be definitively Binary. There are no effective treatments for platinum Resistant OC patients. Should these results -Mid Year confirm earlier data (100% Survival Rates), Gps is immediately worth $1B just for OC. Also, AML Phase 3 Approval zone 4 months away. $Jazz Paid 1.5B for $cpxx when it reported its P3 data .. Tuck a Few away while they’re on sale and ‘stay tuned.’
    https://www.globenewswire.com/news-release/2021/06/30/2255695/0/en/SELLAS-Reports-Promising-Updated-Clinical-Data-and-Initial-Immune-Response-Profiles-from-Ongoing-Phase-1-2-Study-of-Galinpepimut-S-GPS-Combined-with-Keytruda-for-Treating-WT1-Advan.html
    Updated Data Shows 100 Percent of Patients Alive and 45.5 Percent Continuing Investigational Therapy as of the Latest Follow-Up Immune Data Shows GPS...
    Updated Data Shows 100 Percent of Patients Alive and 45.5 Percent Continuing Investigational Therapy as of the Latest Follow-Up Immune Data Shows GPS...
    www.globenewswire.com
  • C
    CMOREGAINS
    Good news fellow Jazz enthusiast! I just noticed the executives buying LOTS of shares. Good sign for us!
  • N
    Noah
    feels nice to see this stock finally be in the profit for me